An international observational study has indicated that certain GLP-1 medications, specifically semaglutide and liraglutide, are associated with a reduced risk of worsening mental health conditions among individuals already diagnosed with mental illnesses. The findings, published in The Lancet Psychiatry, suggest that users of these medications experienced fewer instances of psychiatric hospitalization, mental illness-related sick leave, and self-harm.
Introduction
A recent international observational study has found an association between the use of certain GLP-1 medications, including semaglutide and liraglutide, and a reduced risk of worsening mental health conditions. The research, a collaboration between the University of Eastern Finland, Karolinska Institutet in Stockholm, and Griffith University in Australia, was published in The Lancet Psychiatry.
Study Methodology
The register-based study monitored approximately 95,000 individuals from 2009 to 2022 using Swedish national registers. Participants had an average age of 50.6 years and were diagnosed with depression or an anxiety disorder, having also used antidiabetic medication. Over 20,000 participants utilized GLP-1 medications during the study period.
The investigation aimed to explore connections between metabolic and mental health, recognizing that conditions like diabetes and obesity can heighten mental health symptom risks, while mental disorders can elevate metabolic disease risks.
Key Findings
The study reported that GLP-1 medications were linked to fewer serious mental health outcomes, including psychiatric hospitalization, mental illness-related sick leave, and suicide or self-harm.
Specifically:
- Semaglutide: Users of semaglutide were associated with a 42% lower risk of worsening mental health conditions compared to periods without GLP-1 medication. This included a 44% lower risk of worsening depression, a 38% lower risk of worsening anxiety, and a 47% lower risk of worsening substance use disorder, encompassing hospital care and sickness absence. A reduced risk of suicidal behavior was also noted.
- Liraglutide: Use of liraglutide was associated with an 18% lower risk of worsening mental health.
- Other GLP-1 medications, such as exenatide and dulaglutide, did not demonstrate similar benefits in this study.
Context and Potential Mechanisms
The authors emphasized that as an observational study, these findings indicate an association and do not establish a direct cause-and-effect relationship between the medications and improved mental health. However, the results suggest potential benefits beyond the primary uses of GLP-1 medications for diabetes and weight loss.
GLP-1 medications, such as semaglutide (marketed as Ozempic and Wegovy) and liraglutide (marketed as Saxenda and Victoza), function by mimicking the natural GLP-1 hormone, which assists in regulating appetite and blood sugar.
Researchers proposed several potential contributing factors for the observed association, including reduced alcohol consumption, improved body image resulting from weight loss, better glycemic control in individuals with diabetes, and possible direct neurobiological mechanisms affecting the brain's reward system.
Previous research has linked GLP-1 medications to reduced alcohol use disorder.
The study also highlights the established bidirectional relationship between mental health conditions and metabolic diseases. The World Health Organization (WHO) reports approximately 140 million people in Europe experience a mental health condition, and the International Diabetes Federation (IDF) indicates depression is nearly twice as prevalent in adults with diabetes. This connection is influenced by biological, behavioral, and social factors.
Future Research
Researchers stated that these findings could serve as a foundation for future clinical trials to further investigate the mechanisms and potential therapeutic applications of GLP-1 medications for mental health support.